| Professional Services Industry | Industrials Sector | Mr. Chris Henry Francis Yates CEO | LSE Exchange | - ISIN |
| United Kingdom Country | 84 Employees | - Last Dividend | - Last Split | - IPO Date |
Abingdon Health Plc is a leading entity that specializes in the development, manufacture, and distribution of diagnostic devices, serving an international clientele including regions such as the United Kingdom, the United States, Canada, Europe, and beyond. Established in 2008 and headquartered in York, the United Kingdom, the company is at the forefront of providing innovative solutions in diagnostics, covering a wide array of needs from fertility, health and well-being, to infectious diseases, drug testing, and plant health. Furthermore, Abingdon Health Plc prides itself on its strategic collaborations with significant partners like DeepVerge plc and Vatic Health Limited, enhancing its capabilities in the development, manufacturing, and commercialization of lateral flow tests, thus cementing its role in the diagnostics sector.
A diverse range of self-tests designed for consumers covering fertility, health and well-being, infectious diseases, and drug testing. These tests are crafted to provide quick and reliable results, facilitating early detection and wellness monitoring.
Nucleic acid lateral flow tests that offer rapid results post isothermal amplification. These tests are pivotal for various applications, enabling quick decision-making processes in clinical, research, and industrial settings.
A rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. Designed for efficiency and accuracy, this test plays a crucial role in managing and controlling the spread of COVID-19 by facilitating quick diagnoses.
Diagnostic tests tailored to meet the needs of the agriculture sector, focusing on the health and productivity of plants. These tests are essential for early detection of diseases, ensuring the well-being of crops and securing food supply chains.
These assays are a part of the company’s broader range of diagnostic tests, which include customized solutions for detecting nucleic acids rapidly and efficiently.
A customizable image capturing technology that transforms smartphones into self-sufficient, standalone lateral-flow readers. This innovation democratizes the application of lateral flow assays, offering a practical solution for point-of-care testing.
A revolutionary rapid saliva-based pregnancy test. This product exemplifies the company's dedication to innovating within the diagnostics space, offering a more convenient and non-invasive testing option for pregnancy detection.
Abingdon Health Plc extends its expertise through a wide array of services including contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. This comprehensive service offering supports businesses at various stages of product development and market launch.
The company also offers regulatory consultancy services, providing essential support and guidance for businesses navigating the complex regulatory environment of the diagnostics sector. This service ensures that products meet all necessary standards and regulations for market entry.